Segment Reporting (Tables)

12 Months Ended

Jan. 02, 2026

Segment Reporting [Abstract]

Scheduled of Segment Profit, Including Significant Segment Expenses

The segment and consolidated net income, including significant segment expenses were as follows (in thousands):

	Year Ended December 31,
	2025		2024		2023
Revenues	$	2,320,126	$	2,168,701	$	1,830,208
Less:
Cost of goods sold	83,697		76,216		72,547
Drug discovery	89,931		94,842		215,085
Development	567,843		665,847		669,240
Selling, general, and administrative	446,536		428,962		470,680
Other segment items(1)	260,126		298,350		231,678
Interest income	(69,213)		(77,156)		(86,543)
Provision for income taxes	158,636		160,373		49,756
Segment and consolidated net income	$	782,570	$	521,267	$	207,765

_________________

(1) Other segment items include stock-based compensation, impairment of long-lived assets, restructuring expenses, other research and development expenses, including the allocation of general corporate costs to research and development services and development cost reimbursements in connection with certain of our collaboration arrangements, and other income (expenses), net.